PERKINELMER HOSTS FT-IR BIOMEDICAL IMAGING MEDIA ROUNDTABLE
Event Brings Together Experts from Rutgers University, Hunter College and Brookhaven National Laboratory to Discuss Emerging Application of FT-IR Technology in Disease Research
( NEWARK , N.J. ) – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions, today brought together leading researchers from academia and industry to discuss a novel field of research: the diagnosis of disease and identification of disease-causing agents using infrared (FT-IR) imaging techniques.
IR spectroscopy, commonly used for the analysis of chemical compounds, is also valuable for disease diagnosis due to its ability to detect chemical changes in cells and tissues. By applying FT-IR technology to diseased biological samples, researchers are achieving new insights and breakthroughs. FT-IR brings capabilities to biomedical research that advance the understanding of disease and also facilitate investigation into new methodologies and instrumentation for earlier and more accurate diagnosis than previously possible with other techniques.
Presenters and topics include:
- Max Diem, Ph.D., professor of biochemistry at the City University of New York, Hunter College – “How Infrared Helps Automate Pathology Applications”
- Richard Mendelsohn, Ph.D., professor of chemistry at Rutgers University – “Infrared Imaging: Principles and Molecular Characterization of Osteoporosis”
- Lisa Miller, Ph.D., biophysical chemist from Brookhaven National Laboratory – 'Imaging Protein Misfolding in Alzheimer's Disease and Prion Diseases'
These researchers and others have used the PerkinElmer Spectrum TM Spotlight TM 300 FT-IR imaging system to further their understanding of a growing number of aortic and musculoskeletal diseases. In addition, researchers are developing earlier detection and classification of prostate, lymph, breast and cervical cancer.
“The Spectrum Spotlight 300 FT-IR imaging system offers technology that is enabling surgeons, clinicians and pathologists to investigate new approaches for disease detection,” said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. “These techniques may also lead to earlier detection and the development of less invasive, more effective intervention to improve the lives of patients. ”
For more information including biomedical FT-IR imaging case studies and online seminars, visit www.perkinelmer.com/spotlight
Factors Affecting Future Performance
This press release contains 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results, are deemed to be forward-looking statements. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' “projects,” “forecasts,” 'will' and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption 'Forward-Looking Information and Factors Affecting Future Performance' in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877- PKI -NYSE.
For further information:
Investor Contact:Dan Sutherby
Media Contact: Arika Beaudry